Alvotech
AVT80
ulcerative colitis, Crohn’s disease
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for AVT80 in ulcerative colitis, Crohn’s disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Alvotech announced positive results from a pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio for subcutaneous administration.”